Table 2.
Strategies | Cost | Incr cost | LYs | Incr LYs | ICER/LYs | QALYs | Incr QALYs | ICER/QALYs |
---|---|---|---|---|---|---|---|---|
All patients group | ||||||||
Chemotherapy | 95,715.26 | 0.65 | 0.58 | |||||
Nivolumab plus ipilimumab | 292,319.48 | 196,604.22 | 1.58 | 0.92 | 213,082.80 | 1.11 | 0.53 | 371,861.36 |
Incr cost, incremental cost; Lys, life-years; Incr Lys, incremental life-years; QALYs, quality-adjusted life-years; Incr QALYs, incremental quality-adjusted life-years; ICER, incremental cost-effectiveness ratio.